Robert Allen III Sells 20,679 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 20,679 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $0.72, for a total transaction of $14,888.88. Following the sale, the insider directly owned 195,808 shares of the company’s stock, valued at $140,981.76. The trade was a 9.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Up 10.3%

Shares of NASDAQ:IVVD opened at $0.96 on Thursday. The firm’s 50 day moving average price is $0.77 and its 200-day moving average price is $1.23. Invivyd, Inc. has a twelve month low of $0.48 and a twelve month high of $3.07. The stock has a market capitalization of $282.82 million, a PE ratio of -2.91 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Analysts expect that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on IVVD shares. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. Finally, BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Invivyd has a consensus rating of “Hold” and a consensus target price of $8.00.

More Invivyd News

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

Institutional Trading of Invivyd

Several institutional investors have recently made changes to their positions in the business. Jupiter Topco LLC bought a new stake in Invivyd during the 2nd quarter valued at approximately $30,048,000. Perceptive Advisors LLC bought a new position in Invivyd in the 4th quarter worth approximately $53,809,000. BVF Inc. IL bought a new position in Invivyd in the 4th quarter worth approximately $48,227,000. RA Capital Management L.P. purchased a new stake in Invivyd during the 3rd quarter valued at approximately $18,831,000. Finally, BlackRock Inc. purchased a new stake in Invivyd during the 2nd quarter valued at approximately $14,076,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.